Home › Cancro ovarico › Louisiana
Studi clinici su Cancro ovarico nello stato di Louisiana
19 studi su Cancro ovarico cercano partecipanti presso sedi nello stato di Louisiana.
Città nello stato di Louisiana
Testo ufficiale dello studio (inglese)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Louisiana State University HSC - NO Cancer Center, New Orleans
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 5 ott 2026 · NCT06915025Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
- University Medical Center New Orleans, New Orleans
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT07001748Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Ochsner Medical Center Jefferson, New Orleans
In reclutamentoFase 2
Tutte le età · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT05564377Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Ochsner Clinic Foundation, New Orleans
In reclutamentoStudio osservazionale
Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT05051722A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- Women'S Cancer Care /ID# 276469, Covington
- University Medical Center New Orleans /ID# 274755, New Orleans
- Trials 365 /ID# 274310, Shreveport
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 29 set 2026 · NCT06890338A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Ochsner Clinic Foundation, New Orleans
- Trials 365, Shreveport
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213804A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- Our Lady of the Lake Physician Group - Medical Oncology /ID# 277440, Baton Rouge
In reclutamentoFase 2
Età 18 e oltre · Donne · Aggiornato il 22 set 2026 · NCT07059845A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
- Women's Cancer Care ( Site 0018), Covington
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 17 set 2026 · NCT07318558Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Women'S Cancer Care, Covington
- Trials365, Llc, Shreveport
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 15 set 2026 · NCT07214779A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
- Trials365, Llc, Shreveport
In reclutamentoFase 2
Età da 18 a 99 · Donne · Aggiornato il 15 set 2026 · NCT07023627ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Tulane Cancer Center, New Orleans
- Christus Highland/ Boniol, Shreveport
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT05059444A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
- Women's Cancer Care ( Site 0067), Covington
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 3 set 2026 · NCT06824467A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
- West Jefferson Medical Center, Marrero
- Louisiana State University Health Science Center, New Orleans
- University Medical Center New Orleans, New Orleans
- e altri 1
In reclutamento
Età da 35 a 50 · Donne · Aggiornato il 7 ago 2026 · NCT04251052Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- LSU Health Baton Rouge-North Clinic, Baton Rouge
- Our Lady of the Lake Physician Group, Baton Rouge
- Our Lady of The Lake, Baton Rouge
- e altri 8
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT06580314A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Our Lady of the Lake, Baton Rouge
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 lug 2026 · NCT04657068First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Louisiana State University Health Sciences Center, New Orleans
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 7 lug 2026 · NCT05768139Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Trials365 LLC, Shreveport
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 2 lug 2026 · NCT06819007Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
- LSU Health New Orleans, New Orleans
- University Medical Center New Orleans, New Orleans
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 16 apr 2026 · NCT05659381SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, New Orleans
In reclutamentoStudio osservazionale
Tutte le età · Tutti i sessi · Aggiornato il 28 ott 2025 · NCT03452774Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.